Related Experiment Video
Updated: Jun 27, 2026
07:27
The Murine Choline-Deficient, Ethionine-Supplemented (CDE) Diet Model of Chronic Liver Injury
Published on: October 21, 2017
Thiamine deficiency-related brain dysfunction in chronic liver failure
1Neuroscience Research Unit, Saint-Luc Hospital (CHUM), University of Montreal, 1058, Saint-Denis Street, Montreal, QC H2X 3J4, Canada. roger.butterworth@umontreal.ca
Metabolic Brain Disease
|December 11, 2008
Summary
Chronic liver failure causes thiamine deficiency and increased brain ammonia. Combined, these impair brain energy metabolism and may cause hepatic encephalopathy symptoms, highlighting the need for thiamine supplementation.
Area of Science:
- Biochemistry
- Neuroscience
- Hepatology
Background:
- End-stage chronic liver failure (CLF) leads to thiamine deficiency due to depleted liver stores.
- CLF also causes elevated brain ammonia concentrations.
- Both factors negatively impact brain function.
Purpose of the Study:
- To investigate the combined effects of ammonia and thiamine deficiency on brain metabolism in CLF.
- To explain the neurological symptoms observed in hepatic encephalopathy.
- To underscore the importance of thiamine supplementation in CLF patients.
Main Methods:
- Analysis of alpha-ketoglutarate dehydrogenase activity in the brain.
- Assessment of mitochondrial oxidative deficits.
- Evaluation of brain lactate, oxidative stress, and cytokine levels.
Main Results:
- Thiamine deficiency and ammonia independently decrease alpha-ketoglutarate dehydrogenase activity.
- This enzyme's reduced activity causes mitochondrial dysfunction, energy impairment, and inflammation in the brain.
- Synergistic effects may explain neurological deficits in hepatic encephalopathy.
Conclusions:
- Thiamine deficiency and ammonia toxicity have synergistic detrimental effects on brain metabolism in CLF.
- Unrecognized thiamine deficiency may contribute to persistent neurological symptoms post-treatment or transplant.
- Prompt thiamine supplementation is crucial for managing CLF patients to prevent or mitigate brain damage.
Related Concept Videos
01:29Hepatic Encephalopathy
DefinitionHepatic encephalopathy is a reversible neurologic syndrome that results from advanced liver dysfunction or portosystemic shunting. It leads to disturbances in cognition, behavior, and motor function due to the brain’s exposure to gut-derived toxins that the liver fails to detoxify.EtiologyThis condition develops either in the setting of acute fulminant hepatitis or progressively during chronic liver disease, such as cirrhosis and portal hypertension. Portosystemic shunting—including...
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
01:30Vitamins
Vitamins, derived from the Latin word for life, are essential organic substances required in small quantities for optimal growth and overall well-being. Unlike other organic nutrients, vitamins don't act as sources of energy or building materials but rather facilitate these nutrients' utilization by the body. Vitamins are predominantly coenzymes, assisting enzymes in specific chemical actions, like the oxidation of glucose for energy involving B vitamins. Most vitamins are not produced in our...
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
01:24Cirrhosis II: Pathophysiology
Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...